SCHEMBL30133893

SCHEMBL30133893

CCOC(=O)c1nn(C2CCCCO2)cc1[N+](=O)[O-]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
ALDH1A1 P00352 5/20 0.40
MITF O75030 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
POLB P06746 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
LMNA P02545 2/20 0.40
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
AR P10275 1/20 0.38
ELANE P08246 1/20 0.38
RECQL P46063 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ABL1 P00519 1/20 0.37
HTT P42858 2/20 0.37
USP2 O75604 1/20 0.37
THRB P10828 1/20 0.37
S100A4 P26447 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3576511 0.90 ALDH1A1 (0.40) MAPTALDH1A1POLBMEN1KMT2A
SCHEMBL30079004 0.85 ALDH1A1 (0.39) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL29576377 0.85 ELANE (0.41) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL17926767 0.84 NPC1 (0.46) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL2804353 0.84 HCAR3 (0.38) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL9912458 0.84 LMNA (0.38) MAPTALDH1A1MITFSMN1; SMN2POLB
SCHEMBL23457143 0.83 ELANE (0.39) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL13375094 0.83 ALDH1A1 (0.36) MAPTALDH1A1SMN1; SMN2POLBMEN1
SCHEMBL16654993 0.83 ELANE (0.39) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL29222203 0.83 ELANE (0.39) ALDH1A1SMN1; SMN2MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658656-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES Beone Medicines I GmbH (CH) 2025-12-10 EP disclosed
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-13 US disclosed
CN-119119033-A Pyrazolopyridone compounds 百济神州有限公司 2024-12-13 CN disclosed
US-20240300951-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-09-12 US disclosed
US-20240270751-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-08-15 US disclosed
WO-2024160276-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEIGENE, LTD. (KY) 2024-08-08 WO disclosed
EP-4380936-A1 PYRAZOLOPYRIDINONE COMPOUNDS BeiGene, Ltd. (KY) 2024-06-12 EP disclosed
CN-117836296-A Pyrazolopyridone compounds 百济神州有限公司 2024-04-05 CN disclosed
WO-2023011456-A1 PYRAZOLOPYRIDINONE COMPOUNDS BEIGENE, LTD. (KY) 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300951-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK MAPT 4030/4885ALDH1A1 1296/4885MITF 2365/4885
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKA, DGKK MAPT 4168/4885ALDH1A1 4075/4885MITF 2898/4885
US-20240270751-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK MAPT 4030/4885ALDH1A1 1296/4885MITF 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.